Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Sees Significant Growth in Short Interest

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) was the target of a large growth in short interest in August. As of August 15th, there was short interest totalling 1,970,000 shares, a growth of 5.9% from the July 31st total of 1,860,000 shares. Currently, 4.3% of the company's stock are sold short. Based on an average daily trading volume, of 1,670,000 shares, the days-to-cover ratio is presently 1.2 days.

Amylyx Pharmaceuticals Stock Up 4.7 %

Shares of NASDAQ AMLX traded up $0.10 during mid-day trading on Monday, reaching $2.22. 414,100 shares of the company were exchanged, compared to its average volume of 2,185,571. The stock has a market cap of $150.97 million, a price-to-earnings ratio of -2.07 and a beta of -0.63. Amylyx Pharmaceuticals has a 1 year low of $1.58 and a 1 year high of $22.03. The firm has a 50-day moving average of $2.01 and a 200 day moving average of $3.86.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.73) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.35). The company had revenue of ($1.02) million for the quarter, compared to analysts' expectations of $18.83 million. Amylyx Pharmaceuticals had a negative return on equity of 15.51% and a negative net margin of 17.86%. During the same quarter last year, the company earned $0.31 earnings per share. On average, equities analysts forecast that Amylyx Pharmaceuticals will post -2.27 earnings per share for the current year.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC raised its stake in Amylyx Pharmaceuticals by 52,575.9% in the first quarter. Allspring Global Investments Holdings LLC now owns 15,276 shares of the company's stock valued at $43,000 after buying an additional 15,247 shares during the last quarter. Algert Global LLC acquired a new stake in Amylyx Pharmaceuticals in the second quarter worth about $47,000. CWM LLC boosted its holdings in Amylyx Pharmaceuticals by 104.2% in the second quarter. CWM LLC now owns 28,643 shares of the company's stock worth $54,000 after acquiring an additional 14,613 shares in the last quarter. Quest Partners LLC acquired a new stake in Amylyx Pharmaceuticals in the fourth quarter worth about $89,000. Finally, SG Americas Securities LLC boosted its holdings in Amylyx Pharmaceuticals by 113.6% in the second quarter. SG Americas Securities LLC now owns 55,836 shares of the company's stock worth $106,000 after acquiring an additional 29,697 shares in the last quarter. 95.84% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on AMLX shares. HC Wainwright reissued a "buy" rating and set a $8.00 price target on shares of Amylyx Pharmaceuticals in a research report on Wednesday, July 10th. The Goldman Sachs Group increased their price target on Amylyx Pharmaceuticals from $3.00 to $4.00 and gave the stock a "neutral" rating in a research report on Friday, July 12th. Finally, Mizuho dropped their price target on Amylyx Pharmaceuticals from $4.00 to $3.00 and set a "neutral" rating on the stock in a research report on Tuesday, May 14th. Six research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $17.60.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.